{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:00:06Z","timestamp":1791583206030,"version":"4.3.4"},"reference-count":69,"publisher":"American Academy of Pediatrics (AAP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:p>Inborn errors of metabolism are a heterogeneous group of genetic disorders caused by deficiencies in specific enzymes or proteins, leading to toxic substrate accumulation or deficient product formation. Enzyme replacement therapy (ERT) has emerged as a transformative treatment, particularly for lysosomal storage disorders such as infantile-onset Pompe disease. This review explores the evolution, clinical application, and emerging innovations in ERT, focusing on disorders that present during the neonatal and infantile period. Treatment of patients with Pompe disease illustrates the benefits and limitations of ERT. Early intravenous administration of recombinant acid alpha-glucosidase has dramatically improved survival and cardiac function in affected infants. However, challenges such as immunogenicity, limited central nervous system penetration, and variable skeletal muscle response persist. Novel approaches, such as in utero enzyme replacement therapy, show promise in enhancing outcomes through early intervention and immune tolerance induction. This review also examines ERT in other infantile disorders, outlining efficacy and limitations. Expanding therapeutic frontiers\u2014including gene therapy, gene editing, substrate reduction therapy, and stem cell transplantation\u2014are discussed as complementary or alternative strategies. Despite its success, ERT faces barriers including high cost, limited global access, and the need for ongoing surveillance of long-term outcomes. Addressing these challenges requires investment in research, expanded newborn screening, and equitable access to care. ERT continues to reshape the prognosis of several fatal pediatric metabolic disorders, offering hope for improved quality of life and survival through early and innovative interventions.<\/jats:p>","DOI":"10.1542\/neo.26-12-081","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:03:49Z","timestamp":1764547429000},"page":"e835-e846","source":"Crossref","is-referenced-by-count":4,"title":["Enzyme Replacement Therapy &amp; Other Therapeutic Frontiers in Infantile Metabolic Disorders"],"prefix":"10.1542","volume":"26","author":[{"given":"Hyo-Jung","family":"Choi","sequence":"first","affiliation":[{"name":"1Division of Neonatology, Department of Pediatrics, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achyuth","family":"Sriram","sequence":"additional","affiliation":[{"name":"1Division of Neonatology, Department of Pediatrics, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Sargiotto","sequence":"additional","affiliation":[{"name":"2Division of Clinical Genetics, Human Genetics, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Fajardo-Martinez","sequence":"additional","affiliation":[{"name":"1Division of Neonatology, Department of Pediatrics, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2025113019034366900_r1","volume-title":"Inborn errors of metabolism","author":"Jeanmonod","year":"2025"},{"issue":"24","key":"2025113019034366900_r2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.21037\/atm.2018.11.68","article-title":"Newborn screening and changing face of inborn errors of metabolism in the United States","volume":"6","author":"Kanungo","year":"2018","journal-title":"Ann Transl Med."},{"key":"2025113019034366900_r3","volume-title":"Fabry Disease: Perspectives from 5\u00a0Years of FOS","author":"Neufeld","year":"2006"},{"issue":"3","key":"2025113019034366900_r4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10545-017-0032-8","article-title":"Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923\u20132016)","volume":"40","author":"Ries","year":"2017","journal-title":"J Inherit Metab Dis."},{"issue":"3","key":"2025113019034366900_r5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.20517\/rdodj.2022.09","article-title":"Enzyme replacement therapy: current challenges and drug delivery prospects via extracellular vesicles","volume":"1","author":"Silva","year":"2022","journal-title":"Rare Dis Orphan Drug J."},{"key":"2025113019034366900_r6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv Drug Deliv Rev."},{"issue":"4","key":"2025113019034366900_r7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1542\/peds.2008-0635","article-title":"Lysosomal storage disorders in the newborn","volume":"123","author":"Staretz-Chacham","year":"2009","journal-title":"Pediatrics."},{"issue":"15","key":"2025113019034366900_r8","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging (Albany NY)."},{"issue":"9646","key":"2025113019034366900_r9","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet."},{"issue":"6","key":"2025113019034366900_r10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur J Hum Genet."},{"issue":"1","key":"2025113019034366900_r11","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics."},{"issue":"3","key":"2025113019034366900_r12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol Clin."},{"issue":"5","key":"2025113019034366900_r13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med."},{"issue":"4","key":"2025113019034366900_r14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics."},{"issue":"2","key":"2025113019034366900_r15","first-page":"78","article-title":"Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD)","volume":"32","author":"Toscano","year":"2013","journal-title":"Acta Myol."},{"issue":"1","key":"2025113019034366900_r16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.biochem.031209.093756","article-title":"From serendipity to therapy","volume":"80","author":"Neufeld","year":"2011","journal-title":"Annu Rev Biochem."},{"issue":"13","key":"2025113019034366900_r17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/atm.2019.04.67","article-title":"Progress and challenges of gene therapy for Pompe disease","volume":"7","author":"Ronzitti","year":"2019","journal-title":"Ann Transl Med."},{"issue":"6","key":"2025113019034366900_r18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40291-024-00733-x","article-title":"Advances in Pompe disease treatment: from enzyme replacement to gene therapy","volume":"28","author":"Colella","year":"2024","journal-title":"Mol Diagn Ther."},{"issue":"1","key":"2025113019034366900_r19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JND-230164","article-title":"Long-term outcome of infantile onset Pompe disease patients treated with enzyme replacement therapy - data from a German-Austrian cohort","volume":"11","author":"Pfrimmer","year":"2024","journal-title":"J Neuromuscul Dis."},{"issue":"3","key":"2025113019034366900_r20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res."},{"issue":"16","key":"2025113019034366900_r21","doi-asserted-by":"crossref","first-page":"e94328","DOI":"10.1172\/jci.insight.94328","article-title":"Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease","volume":"2","author":"Kazi","year":"2017","journal-title":"JCI Insight."},{"key":"2025113019034366900_r22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3389\/fimmu.2020.01727","article-title":"Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort","volume":"11","author":"Desai","year":"2020","journal-title":"Front Immunol."},{"key":"2025113019034366900_r23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci."},{"key":"2025113019034366900_r24","doi-asserted-by":"crossref","first-page":"e32132","DOI":"10.1002\/ajmg.c.32132","article-title":"Prenatal delivery of enzyme replacement therapy to fetuses affected by early-onset lysosomal storage diseases","author":"Borges","year":"2025","journal-title":"Am J Med Genet C Semin Med Genet."},{"issue":"23","key":"2025113019034366900_r25","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","article-title":"In utero enzyme-replacement therapy for infantile-onset Pompe\u2019s disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N Engl J Med."},{"key":"2025113019034366900_r26","author":"National Gaucher Foundation"},{"key":"2025113019034366900_r27","volume-title":"Gaucher Disease","author":"Stone","year":"2025"},{"issue":"1","key":"2025113019034366900_r28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/jcm12010085","article-title":"Global incidence and prevalence of Gaucher disease: a targeted literature review","volume":"12","author":"Castillon","year":"2022","journal-title":"J Clin Med."},{"key":"2025113019034366900_r29","article-title":"Gaucher disease","author":"National Organization for Rare Disorders","year":"2024"},{"key":"2025113019034366900_r30","article-title":"What is Gaucher disease?","author":"National Gaucher Foundation"},{"issue":"10","key":"2025113019034366900_r31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"2025113019034366900_r32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2025113019034366900_r33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1358\/dot.2016.52.5.2482878","article-title":"Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia","volume":"52","author":"Hofmann","year":"2016","journal-title":"Drugs Today (Barc)."},{"key":"2025113019034366900_r34","volume-title":"Asfotase Alfa","author":"Health CAfDaTi","year":"2017"},{"issue":"2","key":"2025113019034366900_r35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7\u00a0year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"2025113019034366900_r36","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1210\/jc.2018-02335","article-title":"Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study","volume":"104","author":"Hofmann","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2025113019034366900_r37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone."},{"issue":"1\u20132","key":"2025113019034366900_r38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","article-title":"Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa","volume":"122","author":"Kishnani","year":"2017","journal-title":"Mol Genet Metab."},{"key":"2025113019034366900_r39","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2147\/TCRM.S350762","article-title":"Review of treatment for adenosine deaminase deficiency (ADA) severe combined immunodeficiency (SCID)","volume":"18","author":"Secord","year":"2022","journal-title":"Ther Clin Risk Manag."},{"key":"2025113019034366900_r40","volume-title":"GeneReviews((R))","author":"Hershfield","year":"1993"},{"issue":"3","key":"2025113019034366900_r41","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","article-title":"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"143","author":"Kohn","year":"2019","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"2025113019034366900_r42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imr.13293","article-title":"Gene therapy for adenosine deaminase severe combined immune deficiency-An unexpected journey of four decades","volume":"322","author":"Kohn","year":"2024","journal-title":"Immunol Rev."},{"issue":"6","key":"2025113019034366900_r43","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jaip.2023.01.028","article-title":"Long-term immune reconstitution in ADA-deficient patients treated with elapegademase: a real-world experience","volume":"11","author":"Murguia-Favela","year":"2023","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"2025113019034366900_r44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10875-022-01426-y","article-title":"PEGylated recombinant adenosine deaminase maintains detoxification and lymphocyte counts in patients with ADA-SCID","volume":"43","author":"Dorsey","year":"2023","journal-title":"J Clin Immunol."},{"issue":"1","key":"2025113019034366900_r45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10875-025-01873-3","article-title":"Multi-year registry study of elapegademase treatment in patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) requiring enzyme replacement therapy","volume":"45","author":"Dorsey","year":"2025","journal-title":"J Clin Immunol."},{"issue":"5","key":"2025113019034366900_r46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10875-024-01710-z","article-title":"Treatment with elapegademase restores immunity in infants with adenosine deaminase deficient severe combined immunodeficiency","volume":"44","author":"Hicks","year":"2024","journal-title":"J Clin Immunol."},{"issue":"2","key":"2025113019034366900_r47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat Rev Drug Discov."},{"issue":"5","key":"2025113019034366900_r48","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: An update","volume":"20","author":"Ginn","year":"2018","journal-title":"J Gene Med."},{"issue":"6372","key":"2025113019034366900_r49","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science."},{"issue":"7573","key":"2025113019034366900_r50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature."},{"issue":"1","key":"2025113019034366900_r51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat Med."},{"issue":"6","key":"2025113019034366900_r52","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI30953","article-title":"Gene therapy for severe combined immunodeficiency: are we there yet?","volume":"117","author":"Cavazzana-Calvo","year":"2007","journal-title":"J Clin Invest."},{"issue":"6213","key":"2025113019034366900_r53","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science."},{"issue":"2","key":"2025113019034366900_r54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat Med."},{"issue":"22","key":"2025113019034366900_r55","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N Engl J Med."},{"issue":"3853","key":"2025113019034366900_r56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science."},{"issue":"5","key":"2025113019034366900_r57","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic stem cell gene therapy for storage disease: current and new indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol Ther."},{"issue":"37","key":"2025113019034366900_r58","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2025113019034366900_r59","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41591-022-01691-9","article-title":"Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain","volume":"28","author":"Sailor","year":"2022","journal-title":"Nat Med."},{"issue":"9","key":"2025113019034366900_r60","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41593-020-0654-2","article-title":"Microglia phagocytose myelin sheaths to modify developmental myelination","volume":"23","author":"Hughes","year":"2020","journal-title":"Nat Neurosci."},{"issue":"8","key":"2025113019034366900_r61","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s12098-024-05110-4","article-title":"Hematopoietic stem cell transplantation for storage disorders: present status","volume":"91","author":"Chakraborty","year":"2024","journal-title":"Indian J Pediatr."},{"key":"2025113019034366900_r62","doi-asserted-by":"crossref","first-page":"885639","DOI":"10.3389\/fonc.2022.885639","article-title":"New indications for hematopoietic stem cell gene therapy in lysosomal storage disorders","volume":"12","author":"Rossini","year":"2022","journal-title":"Front Oncol."},{"issue":"10","key":"2025113019034366900_r63","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"2025113019034366900_r64","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J Clin Invest."},{"issue":"10043","key":"2025113019034366900_r65","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet."},{"key":"2025113019034366900_r66","volume-title":"Cardioskeletal Myopathies in Children and Young Adults","author":"El-Gharbawy","year":"2017"},{"issue":"4","key":"2025113019034366900_r67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/diseases4040033","article-title":"Genetic substrate reduction therapy: a promising approach for lysosomal storage disorders","volume":"4","author":"Coutinho","year":"2016","journal-title":"Diseases."},{"issue":"1","key":"2025113019034366900_r68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/ETLS20180058","article-title":"Substrate reduction therapy for inborn errors of metabolism","volume":"3","author":"Yue","year":"2019","journal-title":"Emerg Top Life Sci."},{"issue":"5","key":"2025113019034366900_r69","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mol Med."}],"container-title":["NeoReviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/26\/12\/e835\/1898118\/neoreviews.052025cmerev00081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/26\/12\/e835\/1898118\/neoreviews.052025cmerev00081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:04:01Z","timestamp":1764547441000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/neoreviews\/article\/26\/12\/e835\/205582\/Enzyme-Replacement-Therapy-amp-Other-Therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":69,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/neo.26-12-081","relation":{},"ISSN":["1526-9906"],"issn-type":[{"value":"1526-9906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}